Iovance Biotherapeutics (IOVA) Competitors $7.81 -0.03 (-0.38%) (As of 12/17/2024 05:56 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends IOVA vs. ITCI, ROIV, ASND, RVMD, LNTH, LEGN, NUVL, BPMC, ELAN, and CYTKShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Nuvalent (NUVL), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Legend Biotech Nuvalent Blueprint Medicines Elanco Animal Health Cytokinetics Intra-Cellular Therapies (NASDAQ:ITCI) and Iovance Biotherapeutics (NASDAQ:IOVA) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk. Do insiders and institutionals have more ownership in ITCI or IOVA? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 12.1% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, ITCI or IOVA? Intra-Cellular Therapies has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Which has higher valuation & earnings, ITCI or IOVA? Intra-Cellular Therapies has higher revenue and earnings than Iovance Biotherapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$612.78M15.04-$139.67M-$0.87-99.95Iovance Biotherapeutics$90.86M26.20-$444.04M-$1.49-5.24 Is ITCI or IOVA more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Iovance Biotherapeutics' net margin of -451.25%. Intra-Cellular Therapies' return on equity of -9.93% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Iovance Biotherapeutics -451.25%-58.43%-45.48% Does the MarketBeat Community prefer ITCI or IOVA? Iovance Biotherapeutics received 44 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 74.44% of users gave Iovance Biotherapeutics an outperform vote while only 67.84% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% Iovance BiotherapeuticsOutperform Votes56574.44% Underperform Votes19425.56% Does the media prefer ITCI or IOVA? In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 8 mentions for Iovance Biotherapeutics and 7 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 0.79 beat Iovance Biotherapeutics' score of 0.67 indicating that Intra-Cellular Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ITCI or IOVA? Intra-Cellular Therapies currently has a consensus price target of $97.23, suggesting a potential upside of 11.81%. Iovance Biotherapeutics has a consensus price target of $22.33, suggesting a potential upside of 185.96%. Given Iovance Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85Iovance Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 SummaryIntra-Cellular Therapies beats Iovance Biotherapeutics on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.38B$2.98B$5.17B$9.30BDividend YieldN/A1.85%4.77%4.06%P/E Ratio-5.2446.02132.2217.52Price / Sales26.20409.351,256.58139.03Price / CashN/A182.1340.7837.95Price / Book3.433.924.904.91Net Income-$444.04M-$42.03M$118.85M$225.61M7 Day Performance-9.08%-4.04%14.53%-1.46%1 Month Performance-4.52%6.85%17.44%5.38%1 Year Performance0.39%20.53%35.31%22.72% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.0758 of 5 stars$7.81-0.4%$22.33+186.0%+0.4%$2.38B$90.86M-5.24500Short Interest ↑ITCIIntra-Cellular Therapies4.1678 of 5 stars$84.54+1.8%$97.23+15.0%+32.9%$8.96B$612.78M-95.91560ROIVRoivant Sciences2.667 of 5 stars$12.14+2.5%$17.93+47.7%+8.9%$8.84B$129.13M2.10860Positive NewsASNDAscendis Pharma A/S3.2197 of 5 stars$136.02+4.7%$191.77+41.0%+16.0%$8.25B$327.43M-16.52640Short Interest ↑RVMDRevolution Medicines4.6632 of 5 stars$44.89-0.3%$63.67+41.8%+69.6%$7.55B$11.58M-12.54443Positive NewsLNTHLantheus4.3734 of 5 stars$94.27+1.3%$130.00+37.9%+21.9%$6.55B$1.50B15.42834Positive NewsLEGNLegend Biotech1.6722 of 5 stars$33.83-3.7%$81.54+141.0%-43.4%$6.18B$520.18M-36.971,800NUVLNuvalent2.3475 of 5 stars$86.65-0.2%$112.60+29.9%+9.7%$6.16BN/A-25.0340Positive NewsBPMCBlueprint Medicines2.9172 of 5 stars$95.39+2.4%$122.11+28.0%+9.7%$6.06B$249.38M-44.17640Insider TradeShort Interest ↑ELANElanco Animal Health4.2802 of 5 stars$12.13+0.2%$16.75+38.1%-10.5%$6.00B$4.45B30.259,300CYTKCytokinetics3.9886 of 5 stars$49.17+1.1%$83.93+70.7%+32.5%$5.80B$3.22M-9.04250 Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Roivant Sciences Competitors Ascendis Pharma A/S Competitors Revolution Medicines Competitors Lantheus Competitors Legend Biotech Competitors Nuvalent Competitors Blueprint Medicines Competitors Elanco Animal Health Competitors Cytokinetics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IOVA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IOVA Stock Alerts